Merck & Co., Inc. (NYSE:MRK) Shares Purchased by Almanack Investment Partners LLC.

Almanack Investment Partners LLC. raised its stake in Merck & Co., Inc. (NYSE:MRKFree Report) by 7.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,429 shares of the company’s stock after acquiring an additional 239 shares during the quarter. Almanack Investment Partners LLC.’s holdings in Merck & Co., Inc. were worth $452,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of MRK. Norges Bank purchased a new position in Merck & Co., Inc. during the fourth quarter worth approximately $3,108,366,000. Wellington Management Group LLP grew its position in shares of Merck & Co., Inc. by 6.7% in the third quarter. Wellington Management Group LLP now owns 82,442,666 shares of the company’s stock valued at $8,487,472,000 after purchasing an additional 5,196,914 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Merck & Co., Inc. by 14.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 36,682,866 shares of the company’s stock worth $3,966,029,000 after purchasing an additional 4,731,152 shares in the last quarter. Bank of Nova Scotia boosted its holdings in Merck & Co., Inc. by 352.2% in the 4th quarter. Bank of Nova Scotia now owns 3,144,632 shares of the company’s stock worth $342,814,000 after buying an additional 2,449,211 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado boosted its holdings in Merck & Co., Inc. by 29,914.1% in the 4th quarter. Public Employees Retirement Association of Colorado now owns 2,410,732 shares of the company’s stock worth $262,818,000 after buying an additional 2,402,700 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Down 0.5 %

Shares of MRK stock opened at $125.76 on Tuesday. Merck & Co., Inc. has a 1-year low of $99.14 and a 1-year high of $134.63. The firm has a market cap of $318.53 billion, a PE ratio of 139.73, a price-to-earnings-growth ratio of 2.44 and a beta of 0.38. The company has a 50-day moving average of $129.05 and a two-hundred day moving average of $125.26. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.25 and a quick ratio of 0.99.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its earnings results on Thursday, April 25th. The company reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.13. The firm had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.21 billion. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter last year, the firm earned $1.40 EPS. On average, analysts predict that Merck & Co., Inc. will post 8.62 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, July 8th. Shareholders of record on Monday, June 17th were given a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 2.45%. The ex-dividend date of this dividend was Monday, June 17th. Merck & Co., Inc.’s dividend payout ratio is currently 342.22%.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Wells Fargo & Company boosted their price target on Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 27th. Societe Generale downgraded shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price objective for the company. in a report on Monday, March 11th. Truist Financial upped their price target on Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Argus upgraded Merck & Co., Inc. to a “strong-buy” rating in a research report on Wednesday, June 5th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 target price on shares of Merck & Co., Inc. in a research note on Tuesday, June 18th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.00.

Get Our Latest Stock Analysis on Merck & Co., Inc.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Recommended Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.